Chimeric Therapeutics Ltd

CHM

Company Profile

  • Business description

    Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

  • Contact

    62 Lygon Street
    Level 3, Carlton South
    MelbourneVIC3053
    AUS

    T: +61 398245254

    https://www.chimerictherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.3060.000.68%
CAC 407,820.8812.710.16%
DAX 4024,204.9444.300.18%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,997.700.36-0.00%
HKSE24,590.12386.801.60%
NASDAQ20,640.3354.800.27%
Nikkei 22539,678.02218.400.55%
NZX 50 Index12,689.6310.940.09%
S&P 5006,268.568.810.14%
S&P/ASX 2008,630.3059.900.70%
SSE Composite Index3,505.0014.65-0.42%

Market Movers